Investigation of Fugitive Aerosols Released into the Environment During High-Flow Therapy

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2019 Jun 5

PMID 31159408

Citations 23

Authors

James A McGrath

Ciarrai OToole

Gavin Bennett

Mary Joyce

Miriam A Byrne

Ronan MacLoughlin

Affiliations

Soon will be listed here.

Abstract

Background: Nebulised medical aerosols are designed to deliver drugs to the lungs to aid in the treatment of respiratory diseases. However, an unintended consequence is the potential for fugitive emissions during patient treatment, which may pose a risk factor in both clinical and homecare settings.

Methods: The current study examined the potential for fugitive emissions, using albuterol sulphate as a tracer aerosol during high-flow therapy. A nasal cannula was connected to a head model or alternatively, a interface was connected to a tracheostomy tube in combination with a simulated adult and paediatric breathing profile. Two aerodynamic particle sizers (APS) recorded time-series aerosol concentrations and size distributions at two different distances relative to the simulated patient.

Results: The results showed that the quantity and characteristics of the fugitive emissions were influenced by the interface type, patient type and supplemental gas-flow rate. There was a trend in the adult scenarios; as the flow rate increased, the fugitive emissions and the mass median aerodynamic diameter (MMAD) of the aerosol both decreased. The fugitive emissions were comparable when using the adult breathing profiles for the nasal cannula and tracheostomy interfaces; however, there was a noticeable distinction between the two interfaces when compared for the paediatric breathing profiles. The highest recorded aerosol concentration was 0.370 ± 0.046 mg m from the tracheostomy interface during simulated paediatric breathing with a gas-flow rate of 20 L/min. The averaged MMAD across all combinations ranged from 1.248 to 1.793 µm by the APS at a distance of 0.8 m away from the patient interface.

Conclusions: Overall, the results highlight the potential for secondary inhalation of fugitive emissions released during simulated aerosol treatment with concurrent high-flow therapy. The findings will help in developing policy and best practice for risk mitigation from fugitive emissions.

Citing Articles

From mesenchymal stem cells to their extracellular vesicles: Progress and prospects for asthma therapy.

Chen S, Gao J, Zhang T Asian J Pharm Sci. 2024; 19(4):100942.

PMID: 39253613 PMC: 11382190. DOI: 10.1016/j.ajps.2024.100942.

The Laboratory Characterization of Fugitive Aerosol Emissions From a Standard Jet Nebulizer With and Without a Filtered Mouthpiece.

Dhanak M, Verma S, Hughes P, Ling Ching A, Lo A, Clay C Cureus. 2024; 15(12):e50611.

PMID: 38226095 PMC: 10788659. DOI: 10.7759/cureus.50611.

Characterization of SARS-CoV-2 Aerosols Dispersed During Noninvasive Respiratory Support of Patients With COVID-19.

Ramsey M, Faugno A, Puryear W, Lee B, Foss A, Lambert L Respir Care. 2022; 68(1):8-17.

PMID: 36566031 PMC: 9993517. DOI: 10.4187/respcare.10340.

Evaluation of aerosol drug delivery with concurrent low- and high-flow nasal oxygen.

Murphy B, Mac Giolla Eain M, Joyce M, Fink J, MacLoughlin R ERJ Open Res. 2022; 8(4).

PMID: 36225335 PMC: 9549318. DOI: 10.1183/23120541.00220-2022.

The Impact of Head Model Choice on the In Vitro Evaluation of Aerosol Drug Delivery.

Gallagher L, Joyce M, Murphy B, Mac Giolla Eain M, MacLoughlin R Pharmaceutics. 2022; 14(1).

PMID: 35056920 PMC: 8777612. DOI: 10.3390/pharmaceutics14010024.

References

Berlinski A . Pediatric Aerosol Therapy. Respir Care. 2017; 62(6):662-677. DOI: 10.4187/respcare.05298. View

Ari A, Harwood R, Sheard M, Dailey P, Fink J . In vitro comparison of heliox and oxygen in aerosol delivery using pediatric high flow nasal cannula. Pediatr Pulmonol. 2011; 46(8):795-801. DOI: 10.1002/ppul.21421. View

Dysart K, Miller T, Wolfson M, Shaffer T . Research in high flow therapy: mechanisms of action. Respir Med. 2009; 103(10):1400-5. DOI: 10.1016/j.rmed.2009.04.007. View

Golshahi L, Tian G, Azimi M, Son Y, Walenga R, Longest P . The use of condensational growth methods for efficient drug delivery to the lungs during noninvasive ventilation high flow therapy. Pharm Res. 2013; 30(11):2917-30. PMC: 3800269. DOI: 10.1007/s11095-013-1123-3. View

Dolovich M, Dhand R . Aerosol drug delivery: developments in device design and clinical use. Lancet. 2010; 377(9770):1032-45. DOI: 10.1016/S0140-6736(10)60926-9. View

Bennett G, Joyce M, Sweeney L, MacLoughlin R . In Vitro Determination of the Main Effects in the Design of High-Flow Nasal Therapy Systems with Respect to Aerosol Performance. Pulm Ther. 2020; 4(1):73-86. PMC: 6967237. DOI: 10.1007/s41030-018-0054-x. View

Nazaroff W . Indoor particle dynamics. Indoor Air. 2004; 14 Suppl 7:175-83. DOI: 10.1111/j.1600-0668.2004.00286.x. View

Hui D, Chow B, Ng S, Chu L, Hall S, Gin T . Exhaled air dispersion distances during noninvasive ventilation via different Respironics face masks. Chest. 2009; 136(4):998-1005. PMC: 7094372. DOI: 10.1378/chest.09-0434. View

ORiordan T, Smaldone G . Exposure of health care workers to aerosolized pentamidine. Chest. 1992; 101(6):1494-9. DOI: 10.1378/chest.101.6.1494. View

10.

ElHansy M, Boules M, El Essawy A, Al-Kholy M, Abdelrahman M, Said A . Inhaled salbutamol dose delivered by jet nebulizer, vibrating mesh nebulizer and metered dose inhaler with spacer during invasive mechanical ventilation. Pulm Pharmacol Ther. 2017; 45:159-163. DOI: 10.1016/j.pupt.2017.06.004. View

11.

Acevedo-Bolton V, Ott W, Cheng K, Jiang R, Klepeis N, Hildemann L . Controlled experiments measuring personal exposure to PM2.5 in close proximity to cigarette smoking. Indoor Air. 2013; 24(2):199-212. DOI: 10.1111/ina.12057. View

12.

Smaldone G . Advances in aerosols: adult respiratory disease. J Aerosol Med. 2006; 19(1):36-46. DOI: 10.1089/jam.2006.19.36. View

13.

Berlinski A . Nebulized albuterol delivery in a model of spontaneously breathing children with tracheostomy. Respir Care. 2013; 58(12):2076-86. DOI: 10.4187/respcare.02419. View

14.

Wittgen B, Kunst P, van der Born K, van Wijk A, Perkins W, Pilkiewicz F . Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res. 2007; 13(8):2414-21. DOI: 10.1158/1078-0432.CCR-06-1480. View

15.

McGrath J, Byrne M, Ashmore M, Terry A, Dimitroulopoulou C . Development of a probabilistic multi-zone multi-source computational model and demonstration of its applications in predicting PM concentrations indoors. Sci Total Environ. 2014; 490:798-806. DOI: 10.1016/j.scitotenv.2014.05.081. View

16.

Bhashyam A, Wolf M, Marcinkowski A, Saville A, Thomas K, Carcillo J . Aerosol delivery through nasal cannulas: an in vitro study. J Aerosol Med Pulm Drug Deliv. 2008; 21(2):181-8. DOI: 10.1089/jamp.2007.0662. View

17.

Ari A, Telli Atalay O, Harwood R, Sheard M, Aljamhan E, Fink J . Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respir Care. 2010; 55(7):845-51. View

18.

Somogyi R, Vesely A, Azami T, Preiss D, Fisher J, Correia J . Dispersal of respiratory droplets with open vs closed oxygen delivery masks: implications for the transmission of severe acute respiratory syndrome. Chest. 2004; 125(3):1155-7. PMC: 7094599. DOI: 10.1378/chest.125.3.1155. View

19.

Shults R, Baron S, Decker J, Deitchman S, Connor J . Health care worker exposure to aerosolized ribavirin: biological and air monitoring. J Occup Environ Med. 1996; 38(3):257-63. DOI: 10.1097/00043764-199603000-00010. View

20.

Long C, Suh H, Catalano P, Koutrakis P . Using time- and size-resolved particulate data to quantify indoor penetration and deposition behavior. Environ Sci Technol. 2001; 35(10):2089-99. DOI: 10.1021/es001477d. View